UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045649
Receipt number R000052114
Scientific Title Assessment of depressive disorders based on neuroinflammatory mechanisms using quantitative index of thermal pain perception
Date of disclosure of the study information 2021/10/04
Last modified on 2025/04/08 15:03:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Assessment of depressive disorders based on neuroinflammatory mechanisms using quantitative index of thermal pain perception

Acronym

Assessment of depressive disorders based on the thermal pain perception index

Scientific Title

Assessment of depressive disorders based on neuroinflammatory mechanisms using quantitative index of thermal pain perception

Scientific Title:Acronym

Assessment of depressive disorders based on the thermal pain perception index

Region

Japan


Condition

Condition

Depressive disorders
Other psychiatric disorders

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to quantify intrinsic pain control (placebo analgesia), which reflects reward system reserve, as a behavioral index in patients with depression and other psychiatric disorders, and to examine its relationship with neuroinflammatory and functional and structural neural indices. At the same time, we will examine the impact of chronic insomnia on intrinsic pain control and clarify its significance for the development and maintenance of depression and chronic insomnia. This will be a preliminary study to explore new methods of assessing depression that may contribute to differentiating it from other psychiatric disorders, and to conduct research aimed at developing new differential diagnoses as markers of biological characteristics of depression.

Basic objectives2

Others

Basic objectives -Others

Identification of biological indicators

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Cold and warm detection thresholds (CDT, WDT) and cold and heat pain thresholds (CPT, HPT) measured using Quantitative Sensory Testing: QST

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Patients who are 20 years old or older at the time of obtaining informed consent
(2) Patients with insomnia, or anxiety and depression (based on the assessment by physician)
(3) Patients who can understand the explanatory document of the study and can give written consent of their own free will.

Key exclusion criteria

(1) Patients with serious suicidal ideation and imminent suicide attempt
(2) Patients with a history of substance abuse within 3 months prior to the date of consent
(3) Patients with severe pain, acute trauma, or peripheral nerve paralysis in the forearm of the non-dominant hand for any reason
(4) Other patients who have been considered inappropriate for participation in the study by the physicians involved in this study

Target sample size

150


Research contact person

Name of lead principal investigator

1st name Yuji
Middle name
Last name Ozeki

Organization

Shiga University of Medical Science

Division name

Department of Psychiatry

Zip code

520-2192

Address

Tsukinowa-cho, Seta, Otsu-city, Shiga

TEL

077-548-2291

Email

ozeki@belle.shiga-med.ac.jp


Public contact

Name of contact person

1st name Atsushi
Middle name
Last name Yoshimura

Organization

Shiga University of Medical Science

Division name

Department of Psychiatry

Zip code

520-2192

Address

Tsukinowa-cho, Seta, Otsu-city, Shiga

TEL

077-548-2291

Homepage URL


Email

atusi@belle.shiga-med.ac.jp


Sponsor or person

Institute

Shiga University of Medical Science

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shiga University of Medical Science Ethics Examination Office

Address

Tsukinowa-cho, Seta, Otsu-city, Shiga

Tel

077-548-3576

Email

hqrec@belle.shiga-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 10 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2021 Year 10 Month 04 Day

Date of IRB

2018 Year 06 Month 26 Day

Anticipated trial start date

2021 Year 11 Month 01 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

To clarify the relationship between thermal pain thresholds/placebo effects and psychiatric symptoms such as depression and insomnia.


Management information

Registered date

2021 Year 10 Month 04 Day

Last modified on

2025 Year 04 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052114